Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

被引：227

作者：

Goetz, Matthew P. ^{[1
]}

Sangkuhl, Katrin ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

Schwab, Matthias ^{[4
,5
,6
]}

Province, Michael ^{[7
]}

Whirl-Carrillo, Michelle ^{[2
]}

Symmans, W. Fraser ^{[8
]}

McLeod, Howard L. ^{[9
]}

Ratain, Mark J. ^{[10
]}

Zembutsu, Hitoshi ^{[11
]}

Gaedigk, Andrea ^{[12
,13
]}

van Schaik, Ron H. ^{[14
,15
]}

Ingle, James N. ^{[1
]}

Caudle, Kelly E. ^{[16
]}

Klein, Teri E. ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany

[7] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA

[11] Natl Canc Ctr, Div Human Genet, Res Inst, Tokyo, Japan

[12] Univ Missouri, Div Clin Pharmacol Toxicol & Therapeut Innovat, Childrens Mercy Kansas City, Kansas City, MO 64110 USA

[13] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[14] Erasmus MC, Int Expertctr Pharmacogenet, Dept Clin Chem, Rotterdam, Netherlands

[15] LKCH UMC Utrecht, Utrecht, Netherlands

[16] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; ESTROGEN-RECEPTOR; IN-VITRO; POSTMENOPAUSAL WOMEN; ACTIVE METABOLITE; CODEINE THERAPY; GENOTYPE; CYP2C19-ASTERISK-2; POLYMORPHISMS;

D O I：

10.1002/cpt.1007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

引用

页码：770 / 777

页数：8

共 50 条

[41] CLINICAL PRACTICE GUIDELINE: CYP2D6 GENOTYPING FOR SAFE AND EFFICACIOUS CODEINE THERAPY
Madadi, Parvaz
Amstutz, Ursula
Rieder, Michael
Ito, Shinya
Fung, Vincent
Hwang, Soomi
Turgeon, Jacques
Michaud, Veronique
Koren, Gideon
Carleton, Bruce C.
JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2013, 20 (03): : E369 - E396
[42] CYP2D6 genotype and tamoxifen response
James M Rae
Matthew P Goetz
Daniel F Hayes
James N Ingle
Lang Li
Anna Maria Storniolo
Vered Stearns
David A Flockhart
Breast Cancer Research, 7
[43] Tamoxifen and CYP2D6: A Contradiction of Data
Hertz, Daniel L.
McLeod, Howard L.
Irvin, Dwilliam J., Jr.
ONCOLOGIST, 2012, 17 (05): : 620 - 630
[44] CYP2D6 Genotype and Adjuvant Tamoxifen
Berry, D. A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 138 - 140
[45] CYP2D6 genotype and tamoxifen response
Rae, JM
Goetz, MP
Hayes, DF
Ingle, JN
Li, L
Storniolo, AM
Stearns, V
Flockhart, DA
BREAST CANCER RESEARCH, 2005, 7 (05)
[46] CYP2D6 and Tamoxifen: Awaiting the Denouement
Brauch, Hiltrud B.
Schroth, Werner
Ingle, James N.
Goetz, Matthew P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4589 - 4590
[47] Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?
Huber-Wechselberger, Ariana E.
Niedetzky, Paul
Aigner, Irene
Haschke-Becher, Elisabeth
WIENER MEDIZINISCHE WOCHENSCHRIFT, 2012, 162 (11-12) : 252 - 261
[48] Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy
Lyon, Elaine
Foster, Julie Gastier
Palomaki, Glenn E.
Pratt, Victoria M.
Reynolds, Kristen
Sabato, M. Fernanda
Scott, Stuart A.
Vitazka, Patrik
GENETICS IN MEDICINE, 2012, 14 (12) : 990 - 1000
[49] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C9andHLA-BGenotypes and Phenytoin Dosing: 2020 Update
Karnes, Jason H.
Rettie, Allan E.
Somogyi, Andrew A.
Huddart, Rachel
Fohner, Alison E.
Formea, Christine M.
Ta Michael Lee, Ming
Llerena, Adrian
Whirl-Carrillo, Michelle
Klein, Teri E.
Phillips, Elizabeth J.
Mintzer, Scott
Gaedigk, Andrea
Caudle, Kelly E.
Callaghan, John T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) : 302 - 309
[50] CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
Nahid, Noor A. A.
Johnson, Julie A. A.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (11) : 769 - 785

← 1 2 3 4 5 →